MedTrace Logo

A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer

NCT07468396 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2026-03-12

No results posted yet for this study

Summary

A Phase I Clinical Study of GLR2037 in Patients with Advanced Prostate Cancer

Conditions

Interventions

DRUG

GLR2037

GLR2037 administered QD for 28 day cycles.

Sponsors & Collaborators

  • Gan & Lee Pharmaceuticals.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2031-10-30
Completion
2033-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07468396 on ClinicalTrials.gov